Compare Nutanix Inc (NTNX) vs 10X Genomics Inc (TXG) Price & Performance

Nutanix (NTNX) trades at $67.49, down 0.84% on the day, with strong technical indicators showing a bullish trend. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49. Recent recognition in Gartner's Magic Quadrant for container management and strong conference presentations highlight ongoing business momentum. Valuation metrics show a P/E of 12.95 and P/S of 6.85, with exceptional profitability margins including 86.8% gross margin and 52.81% net income margin.

The outlook remains positive with analyst consensus price target of $77.20 representing 14% upside potential. Key opportunities include continued hybrid cloud adoption and AI infrastructure demand, while risks involve competitive pressures and execution challenges in maintaining growth momentum. Cash flow trends show improvement with 2026 operating cash flow projected at $917 million, supporting the company's strategic investments.

TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.

Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.